[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053914":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":35,"collaborators":10,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Physicians group",null,"Physicians who have experience in the treatment and management of stage IV NSCLC patients with 1L EGFR-TKI.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patinet group","Patients receiving or who have received 1L EGFR-TKI treatment for stage IV NSCLC",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"Research Site","RECRUITING","Chengdu","610000","China","CN",{"type":30,"coordinates":31},"Point",[32,33],104.06667,30.66667,{"lat":33,"lon":32},{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100053914","choicedecision-factor-of-egfr-tki-in-chinese-iv-nsclc-100053914",false,"NCT07413757","CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC","A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)","CHOICE","Inclusion Criteria:\n\nThe following inclusion criteria must be met in order to be enrolled in the stage 1:\n\nPatient:\n\n* Provide informed consent\n* 18 years or older\n* Diagnosed with stage IV NSCLC\n* Currently receiving or previously received 1L EGFR-TKI treatment\n* Without communication barrier\n* Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter\n\nPhysician:\n\n* Provide informed consent\n* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals\n* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month\n* Holding the title of associate chief physician or higher\n\nThe following inclusion criteria must be met in order to be enrolled in the stage 2:\n\nPatient:\n\n* Provide informed consent\n* 18 years or older\n* Diagnosed with stage IV NSCLC\n* Currently receiving or previously received 1L EGFR-TKI treatment\n* Without communication barrier\n* Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter\n\nPhysician:\n\n* Provide informed consent\n* Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals\n* Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month\n* Holding the title of attending physician or higher\n\nExclusion Criteria:\n\nNot applicable.","ALL","18 Years",{"count":48,"type":49},590,"ESTIMATED","OBSERVATIONAL","This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.",[53],"Non-Small Cell Lung Cancer",[55],"NSCLC;patients and physicians;survey;EGFR-TKI;patient preference;physician preference","2026-07-10",{"date":58,"type":59},"2026-07-13","ACTUAL",{"date":61,"type":59},"2026-03-02",{"date":63,"type":49},"2026-07-31",{"name":5,"class":6},1]